Combinations of seed amplification assays that identify the underlying proteinopathy together with other biomarkers, for example, neurofilament light chain as a measure of neuroaxonal breakdown, have the potential to further improve diagnostic accuracy. The gene discussed is NEFL; the disease is proteostasis deficiencies.